![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Kyowa Kirin’s Poteligeo Gains European Marketing Authorization
Kyowa Kirin’s Poteligeo Gains European Marketing Authorization
![](https://www.fdanews.com/ext/resources/test/Device_Images6/EuropeanCommissiononFloor.gif?t=1540854777&width=430)
December 10, 2018
The European Commission granted marketing authorization for Kyowa Kirin’s Poteligeo (mogamulizumab), a treatment for adults with mycosis fungoides or Sézary syndrome who have undergone at least one prior systemic therapy.
The two cancers are the most common subtypes of cutaneous T-cell lymphoma, a rare form of non-Hodgkin’s lymphoma.
Poteligeo targets CC chemokine receptor 4-expressing T-cells in the patient’s blood and skin to manage symptoms. It is the first biologic agent targeting CCR4 to be approved in Europe.
Upcoming Events
-
21Oct